VIMTALABS.NS
Vimta Labs Limited [VIMTALABS.NS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
VIMTALABS.NS Stock Summary
Top 10 Correlated Stocks
VIMTALABS.NS
In the News
VIMTALABS.NS Financial details
Company Rating
Buy
Market Cap
10.6B
Income
413.36M
Revenue
3.2B
Book val./share
-
Cash/share
-
Dividend
2
Dividend %
0.45%
Employees
1.37K
Optionable
No
Shortable
Yes
Earnings
01 May 2024
P/E
23.06
Forward P/E
-
PEG
-2154.96
P/S
3.14
P/B
3.3
P/C
-
P/FCF
-
Quick Ratio
1.92
Current Ratio
2.69
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
18.67
EPS next Y
-
EPS next Q
-
EPS this Y
16.48%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
13.71%
Revenue last 5Y
8.39%
Revenue Q/Q
11.27%
EPS Q/Q
59.79%
-
-
-
-
SMA20
0.86%
SMA50
3.76%
SMA100
13.01%
Inst Own
-
Inst Trans
-
ROA
11%
ROE
15%
ROC
0.18%
Gross Margin
77%
Oper. Margin
19%
Profit Margin
14%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
347.3-623.15
52W High
-27.8%
52W Low
+29.63%
RSI
44
Rel Volume
0.44
Avg Volume
56.83K
Volume
24.85K
Perf Week
-6.4%
Perf Month
-14.55%
Perf Quarter
-10.79%
Perf Half Y
-19.02%
-
-
-
-
Beta
0.765
-
-
Volatility
12.5%, 22.42%
Prev Close
-1.32%
Price
449.8
Change
-2.26%
VIMTALABS.NS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 96.18 | 81.72 | 94.34 | 124.82 | 143.79 | |
| Net income per share | 11.45 | 3.1 | 9.68 | 18.69 | 21.77 | |
| Operating cash flow per share | 17.71 | 11.01 | 16.82 | 26.72 | 39.74 | |
| Free cash flow per share | 10.23 | 3.87 | 1.85 | 9.2 | 17.23 | |
| Cash per share | 1.42 | 2.91 | 2.98 | 5.07 | 18.45 | |
| Book value per share | 77.6 | 78.2 | 87.92 | 105.84 | 127.34 | |
| Tangible book value per share | 77.6 | 73.15 | 82.88 | 97.27 | 119.31 | |
| Share holders equity per share | 77.6 | 78.2 | 87.92 | 105.84 | 127.34 | |
| Interest debt per share | 13.08 | 16.15 | 14.54 | 9.12 | 7.97 | |
| Market cap | 4.38B | 1.32B | 3.57B | 6.99B | 6.95B | |
| Enterprise value | 4.61B | 1.6B | 3.81B | 7.07B | 6.79B | |
| P/E ratio | 17.29 | 19.28 | 16.67 | 16.91 | 14.42 | |
| Price to sales ratio | 2.06 | 0.73 | 1.71 | 2.53 | 2.18 | |
| POCF ratio | 11.18 | 5.42 | 9.6 | 11.83 | 7.9 | |
| PFCF ratio | 19.36 | 15.44 | 87.18 | 34.35 | 18.21 | |
| P/B Ratio | 2.55 | 0.76 | 1.84 | 2.99 | 2.46 | |
| PTB ratio | 2.55 | 0.76 | 1.84 | 2.99 | 2.46 | |
| EV to sales | 2.17 | 0.88 | 1.83 | 2.56 | 2.13 | |
| Enterprise value over EBITDA | 7.04 | 4.91 | 6.5 | 8.16 | 6.9 | |
| EV to operating cash flow | 11.77 | 6.56 | 10.25 | 11.98 | 7.72 | |
| EV to free cash flow | 20.38 | 18.68 | 93.1 | 34.77 | 17.81 | |
| Earnings yield | 0.06 | 0.05 | 0.06 | 0.06 | 0.07 | |
| Free cash flow yield | 0.05 | 0.06 | 0.01 | 0.03 | 0.05 | |
| Debt to equity | 0.15 | 0.19 | 0.16 | 0.08 | 0.05 | |
| Debt to assets | 0.11 | 0.14 | 0.11 | 0.06 | 0.04 | |
| Net debt to EBITDA | 0.35 | 0.85 | 0.41 | 0.1 | -0.16 | |
| Current ratio | 2.13 | 1.67 | 2.05 | 2.6 | 2.86 | |
| Interest coverage | 14.76 | 4.55 | 20.88 | 68.71 | 25.57 | |
| Income quality | 1.11 | 2.94 | 1.3 | 1.06 | 1.35 | |
| Dividend Yield | 0.01 | 0.04 | 0 | 0.01 | 0.01 | |
| Payout ratio | 0.21 | 0.78 | 0 | 0.11 | 0.09 | |
| Sales general and administrative to revenue | 0.04 | 0.05 | 0.04 | 0.03 | 0.03 | |
| Research and developement to revenue | 0 | 0 | 0.01 | 0 | 0 | |
| Intangibles to total assets | -0.03 | 0.02 | 0.02 | 0.06 | 0.05 | |
| Capex to operating cash flow | -0.42 | -0.65 | -0.89 | -0.66 | -0.57 | |
| Capex to revenue | -0.08 | -0.09 | -0.16 | -0.14 | -0.16 | |
| Capex to depreciation | -0.84 | -0.75 | -1.43 | -1.66 | -1.62 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0.01 | 0.01 | |
| Graham number | 141.38 | 73.81 | 138.4 | 210.99 | 249.74 | |
| ROIC | 0.17 | 0.04 | 0.12 | 0.17 | 0.17 | |
| Return on tangible assets | 0.1 | 0.03 | 0.08 | 0.14 | 0.14 | |
| Graham Net | -1.67 | -3.55 | -2.15 | 5.54 | 14.3 | |
| Working capital | 490.17M | 382.98M | 566.25M | 766.08M | 1.06B | |
| Tangible asset value | 1.78B | 1.67B | 1.89B | 2.15B | 2.64B | |
| Net current asset value | 264.42M | 230.44M | 305.61M | 511.43M | 831.19M | |
| Invested capital | 0.15 | 0.19 | 0.16 | 0.08 | 0.05 | |
| Average receivables | 650.04M | 663.27M | 741.93M | 845.91M | 837.42M | |
| Average payables | 120.03M | 107.66M | 126.65M | 135.86M | 133.9M | |
| Average inventory | 171.29M | 180.86M | 158.83M | 160.06M | 199.99M | |
| Days sales outstanding | 113.35 | 134.58 | 143.1 | 115.63 | 91.85 | |
| Days payables outstanding | 68.92 | 71.31 | 88.57 | 56.88 | 71.36 | |
| Days of inventory on hand | 118.96 | 116.34 | 87.41 | 80.08 | 111.81 | |
| Receivables turnover | 3.22 | 2.71 | 2.55 | 3.16 | 3.97 | |
| Payables turnover | 5.3 | 5.12 | 4.12 | 6.42 | 5.11 | |
| Inventory turnover | 3.07 | 3.14 | 4.18 | 4.56 | 3.26 | |
| ROE | 0.15 | 0.04 | 0.11 | 0.18 | 0.17 | |
| Capex per share | -7.48 | -7.15 | -14.97 | -17.52 | -22.51 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 35 | 36.97 | 37.71 | 33.15 | 36.85 | |
| Net income per share | 4.63 | 5.73 | 5.51 | 2.86 | 4.57 | |
| Operating cash flow per share | 7.1 | 7.27 | 7.67 | 8.05 | 7.84 | |
| Free cash flow per share | 7.1 | 7.27 | 7.67 | 8.05 | 7.84 | |
| Cash per share | 0 | 18.45 | 0 | 12.54 | 0 | |
| Book value per share | 0 | 127.34 | 0 | 134 | 0 | |
| Tangible book value per share | 0 | 119.31 | 0 | 126.63 | 0 | |
| Share holders equity per share | 0 | 127.34 | 0 | 134 | 0 | |
| Interest debt per share | 0.3 | 6.89 | 0.2 | 9 | 0.24 | |
| Market cap | 9.65B | 6.95B | 9.03B | 12.81B | 8.98B | |
| Enterprise value | 9.65B | 6.79B | 9.03B | 12.82B | 8.98B | |
| P/E ratio | 23.55 | 13.69 | 18.52 | 50.66 | 22.17 | |
| Price to sales ratio | 12.47 | 8.49 | 10.82 | 17.45 | 11 | |
| POCF ratio | 61.47 | 43.19 | 53.18 | 71.85 | 51.67 | |
| PFCF ratio | 61.47 | 43.19 | 53.18 | 71.85 | 51.67 | |
| P/B Ratio | 0 | 2.46 | 0 | 4.32 | 0 | |
| PTB ratio | 0 | 2.46 | 0 | 4.32 | 0 | |
| EV to sales | 12.47 | 8.3 | 10.82 | 17.46 | 11 | |
| Enterprise value over EBITDA | 42.73 | 27.33 | 36.65 | 71.52 | 39.52 | |
| EV to operating cash flow | 61.47 | 42.22 | 53.18 | 71.87 | 51.67 | |
| EV to free cash flow | 61.47 | 42.22 | 53.18 | 71.87 | 51.67 | |
| Earnings yield | 0.01 | 0.02 | 0.01 | 0 | 0.01 | |
| Free cash flow yield | 0.02 | 0.02 | 0.02 | 0.01 | 0.02 | |
| Debt to equity | 0 | 0.05 | 0 | 0.07 | 0 | |
| Debt to assets | 0 | 0.04 | 0 | 0.05 | 0 | |
| Net debt to EBITDA | 0 | -0.62 | 0 | 0.02 | 0 | |
| Current ratio | 0 | 2.86 | 0 | 2.69 | 0 | |
| Interest coverage | 22.56 | 67.75 | 36.72 | 14.64 | 26.2 | |
| Income quality | 1.53 | 1.27 | 1.39 | 2.82 | 1.72 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0.05 | 0 | 0.04 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0 | 128.14 | 0 | 92.78 | 0 | |
| ROIC | 0 | 0.04 | 0 | 0.02 | 0 | |
| Return on tangible assets | 0 | 0.04 | 0 | 0.02 | 0 | |
| Graham Net | 0 | 14.3 | 0 | 9.85 | 0 | |
| Working capital | 0 | 1.06B | 0 | 974.82M | 0 | |
| Tangible asset value | 0 | 2.64B | 0 | 2.8B | 0 | |
| Net current asset value | 0 | 831.19M | 0 | 746.47M | 0 | |
| Invested capital | 0 | 0.05 | 0 | 0.07 | 0 | |
| Average receivables | 429.65M | 400.35M | 400.35M | 415.36M | 415.36M | |
| Average payables | 57.04M | 72.2M | 72.2M | 46.76M | 46.76M | |
| Average inventory | 92.27M | 113.11M | 113.11M | 122.48M | 122.48M | |
| Days sales outstanding | 0 | 88.07 | 0 | 101.85 | 0 | |
| Days payables outstanding | 0 | 68.51 | 0 | 46.03 | 0 | |
| Days of inventory on hand | 0 | 107.33 | 0 | 120.57 | 0 | |
| Receivables turnover | 0 | 1.02 | 0 | 0.88 | 0 | |
| Payables turnover | 0 | 1.31 | 0 | 1.96 | 0 | |
| Inventory turnover | 0 | 0.84 | 0 | 0.75 | 0 | |
| ROE | 0 | 0.05 | 0 | 0.02 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
VIMTALABS.NS Frequently Asked Questions
What is Vimta Labs Limited stock symbol ?
Vimta Labs Limited is a IN stock and trading under the symbol VIMTALABS.NS
What is Vimta Labs Limited stock quote today ?
Vimta Labs Limited stock price is $449.8 today.
Is Vimta Labs Limited stock public?
Yes, Vimta Labs Limited is a publicly traded company.
Something similar
Company Profile
- Volume Average 56.83K
- Market Capitalization 10.6B
- Employee 1.37K
- CEO Dr. Sivalinga Prasad Vasireddi
- Headquarters Hyderabad,IN
- IPO Date 2005-12-15
-
Website
https://www.vimta.com 
Vimta Labs Limited provides contract research and testing services in India and internationally. It offers laboratory, food and water testing and analysis, preclinical and clinical research, biological molecule structural and functional analysis, environmental assessment, and clinical reference laboratory services. The company serves pharmaceutical, biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device, and various other industries. Vimta Labs Limited was founded in 1984 and is headquartered in Hyderabad, India.
